Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Liraglutide

Nature Reviews Drug Discovery volume 9, pages 267–268 (2010)Cite this article

Subjects

Abstract

In January 2010, liraglutide (Victoza; Novo Nordisk) — an injectable glucagon-like peptide 1 receptor agonist — was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nathan, D. M. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193–203 (2009).

    Article  CAS  Google Scholar 

  2. Lovshin, J. A. & Drucker, D. J. Incretin-based therapies for type 2 diabetes mellitus. Nature Rev. Endocrinol. 5, 262–269 (2009).

    Article  CAS  Google Scholar 

  3. Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664–1669 (2000).

    Article  CAS  Google Scholar 

  4. US Food and Drug Administration. FDA labelling information — Victoza (liraglutide). FDA website [online], (2010).

  5. Garber, A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473–481 (2009).

    Article  CAS  Google Scholar 

  6. Nauck, M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32, 84–90 (2009).

    Article  CAS  Google Scholar 

  7. Marre, M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet. Med. 26, 268–278 (2009).

    Article  CAS  Google Scholar 

  8. Russell-Jones, D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52, 2046–2055 (2009).

    Article  CAS  Google Scholar 

  9. Zinman, B. et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32, 1224–1230 (2009).

    Article  CAS  Google Scholar 

  10. Buse, J. B. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47 (2009).

    Article  CAS  Google Scholar 

  11. Drucker, D. J. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372, 1240–1250 (2008).

    Article  CAS  Google Scholar 

  12. Drucker, D. J. et al. Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits. Diabetes Care 33, 428–433 (2010).

    Article  CAS  Google Scholar 

  13. Bunck, M. C. et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32, 762–768 (2009).

    Article  CAS  Google Scholar 

  14. Knudsen, L. B. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 4 Mar 2010 (doi: 10.1210/en.2009–1272)

  15. Ban, K. et al. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J. Am. Soc. Hyperten. 3, 245–259 (2009).

    Article  Google Scholar 

  16. IMS MIDAS (IMS Health, 2009).

  17. Vosser, R. Hauber, A. & Gordon, J. D. Europe Equity Research Report (J. P. Morgan, 5 Feb 2010).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Daniel J. Drucker is at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, TCP51004 Toronto, Ontario, Canada M5G 1X5. d.drucker@utoronto.ca,

    Daniel J. Drucker

  2. Argyris Dritselis is at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. ADritselis@be.imshealth.com,

    Argyris Dritselis

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Daniel J. Drucker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Argyris Dritselis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Daniel J. Drucker has served as an advisor or consultant within the past 12 months to Amylin Pharmaceuticals, Arena Pharmaceuticals Inc., Arisaph Pharmaceuticals Inc., Eli Lilly Inc, GlaxoSmithKline, Hoffman LaRoche Inc, Isis Pharmaceuticals Inc., Merck Research Laboratories, Metabolex Inc., Novartis Pharmaceuticals, Novo Nordisk Inc., Phenomix Inc, and Transition Pharmaceuticals Inc. Mt. Sinai Hospital receives research funding for Dr Drucker's preclinical studies on liraglutide. Neither Dr Drucker or his family members hold stock directly or indirectly in any of these companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drucker, D., Dritselis, A. & Kirkpatrick, P. Liraglutide. Nat Rev Drug Discov 9, 267–268 (2010). https://doi.org/10.1038/nrd3148

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3148

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research